Notice type: 3rd Party Publications
Typographical Error - Direct Healthcare Professional Communication (DHPC) letter for Caprelsa (vandetanib) dated 10th January 2023: In the ‘Background information’ section, the proportion of RET mutant positive patients treated with placebo who had no disease progression at 2 years was incorrectly stated as 14.9%. This should read 40.1%. The amended DHPC letter is available at the link below.
Problem Or Issue:
Important Safety Information from Sanofi-Aventis Ireland Limited regarding Caprelsa (vandetanib): Restriction of indication
Important Safety Information – Caprelsa (vandetanib)